On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active pharmaceutical ingredients (APIs) from manufacturers not included on its newly established Green List.[1] This action follows FDAs September 5 th announcement of the Green List initiative to curb illegal imports of semaglutide, tirzepatide, and other corresponding APIs.[2] Together, the Green List and Import Alert form FDAs most aggressive enforcement measures to date against GLP-1 imports
Resumen Hoy disponemos de herramientas eficaces para tratar la obesidad: desde frmacos como semaglutida o tirzepatida hasta el baln intragstrico
What options exist for non-responders
With coverage Generic lisdexamfetamine at preferred Part D tier: cost-share depends on Part D phase (deductible, initial coverage, catastrophic) and specific Humana plan
Antes de empezar, piensa en tu estado de salud, tus objetivos y si vale la pena hablar con un profesional